EI
NERV icon

EAM Investors’s Minerva Neurosciences NERV Stock Holding History

EAM Investors’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-17,211
Closed -$1.62M – 353
2016
Q4 		$1.62M Sell
17,211
-6,521
-27% -$666K 0.22% 223
2016
Q3 		$2.68M Sell
23,732
-896
-4% -$86.9K 0.36% 153
2016
Q2 		$2.01M Buy
+24,628
New +$1.57M 0.3% 176

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

EAM Investors's NERV Position: Q1 2017 in Review

EAM Investors sold out of Minerva Neurosciences (NERV) in Q1 2017, closing a stake of 17,211 shares — an estimated $1.62M sold.

EAM Investors first reported a position in NERV in Q2 2016 and held it in 3 quarters. The position peaked at $2.68M in Q3 2016. 71 funds tracked by Wall St. Rank hold NERV as of Q1 2017.

  • EAM Investors reported no remaining Minerva Neurosciences position as of Q1 2017 after selling out during the quarter.
  • EAM Investors sold 17,211 Minerva Neurosciences shares in Q1 2017, an estimated $1.62M.
  • EAM Investors first reported a position in Minerva Neurosciences in Q2 2016 and held it in 3 quarters.
  • EAM Investors's Minerva Neurosciences position peaked at $2.68M in Q3 2016.
  • 71 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q1 2017.

Based on EAM Investors's 13F filing for Q1 2017, filed 10 May 2017.